This site is intended for UK Healthcare Professionals only

UK/FLY/2023/2636 v3| November 2023


New approaches for the optimal management of hypovitaminosis D

Coming soon on-demand, ‘New approaches for the optimal management of hypovitaminosis D’ webinar with our guest speakers Dr Roger Henderson and Professor Esteban Jodar. They will help you to explore Vitamin D deficiency in the UK and look at new approaches for the optimal management of hypovitaminosis D.


Flynn is a privately held pharmaceutical company with interests in secondary care and specialist medicine in both adult and paediatric patients.

Our portfolio of products

The company is engaged in a wide range of therapy areas including general medicine, NDD, psychiatry, paediatrics, post-operative pain management, anti-infective medicine, women's health, and emergency medicine. We supply both branded and generic medicines including a wide range of injectable and oral antibiotics.

Flynn focuses on providing medicines for many groups of patients, often by re-discovering and re-energising already established drugs and branded pharmaceutical products. We seek to continue to deliver patient benefits through introducing new products, improving existing formulations or adding new indications.


Formulation: Soft capsules (calcifidiol monohydrate)


  • Treatment of vitamin D deficiency in adults.
  • Prevention of vitamin D deficiency in adults with identified risks.
  • As an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.


Send a virtual meeting request